Prime Medicine, Inc Common Stock

Yahoo Finance • 9 months ago

2 Magnificent Growth Stocks With Room to Run

Small-cap growth stocks have markedly underperformed the S&P 500 over the past three years. This trend is largely due to rising interest rates and investors' preference for a handful of large-cap companies specializing in artificial intell... Full story

Yahoo Finance • last year

Prime Medicine to Present at Upcoming Investor Conferences

Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that company man... Full story

Yahoo Finance • last year

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- Shared detailed safety evaluation of le... Full story

Yahoo Finance • last year

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

Up to 83% of Hepatocytes (up to 50% whole liver) Precisely Edited for p.L358fs Mutation Following IV Infusion of Prime Editor in NHPs with No Safety Concerns Observed; Editing Well Above Anticipated Threshold Necessary to Reverse Disease M... Full story

Yahoo Finance • last year

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

New In Vivo Data in Humanized Mouse Model Demonstrate that Prime Editing Can Correct Predominant Mutations Accounting for Approximately 60% of Patients with RHO adRP Up to 70% Precise Correction at RHO p.P23H Mutation and up to 65% at RHO... Full story

Yahoo Finance • last year

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Company... Full story

Yahoo Finance • 2 years ago

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

-- Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform -- -- Aim to reduce toxicity of conditioning regimens and introduce new therapeutic option... Full story

Yahoo Finance • 2 years ago

Prime Medicine to Present at Virtual Investor Conferences in May

CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesd... Full story

Yahoo Finance • 2 years ago

Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting

Data demonstrated Prime Editors efficiently, reproducibly and durably corrected the causative mutation of CGD, supporting advancement of development candidate PM359 New preclinical data highlighted ability of PASSIGE™ platform to generate... Full story

Yahoo Finance • 2 years ago

Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates

-- New data further demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting potential of PASSIGE platform to multiplex edit CAR-T cells to be presented at ASGCT Annual Meeting -- -- Expanded Board of D... Full story

Yahoo Finance • 2 years ago

Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gotte... Full story

Yahoo Finance • 2 years ago

Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

-- Announced preclinical data providing further proof-of-concept for Prime Editing’s ability to achieve restoration of genetic function, as well as new preliminary safety analyses demonstrating no detected off-target activity -- -- Nomina... Full story

Yahoo Finance • 2 years ago

Prime Medicine to Present at Cowen 43rd Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottes... Full story

Yahoo Finance • 2 years ago

Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities

-- New preclinical data in Friedrich’s ataxia and cystic fibrosis provided further proof-of-concept for Prime Editing’s ability to achieve restoration of genetic function -- -- New preliminary safety analyses demonstrated no detected off-t... Full story